Innovative dynamic gas-assisted coextrusion process for scalable production of personalized core-shell supplements with controlled dosage and release profiles, significantly increasing manufacturing throughput.
The high-throughput coextrusion process represents a breakthrough in the manufacturing of personalized supplements. Utilizing a dynamic gas-assisted coextrusion method, this platform fabricates custom core-shell drug structures rapidly, achieving scalability that current 3D printing methods cannot match. The core can contain multiple active ingredients, while the shell modulates drug release and protects the core. This technology holds promise for enhancing the practicality of personalized medicine by allowing for custom dosages and controlled release profiles.
Currently at TRL 4, this technology has been validated in a laboratory setting. Future validation plans include expanding material compatibility, establishing processing parameters, and validating structure and performance with various vitamins, minerals, and supplements.
Washington State University is a comprehensive public land‑grant research university serving the state through a multi‑campus system anchored in Pullman. Industry engagement runs through a research and technology park in Pullman, a health sciences campus in Spokane integrated with regional hospitals, and a statewide extension network linking faculty with companies and communities. The Tri‑Cities campus sits minutes from a U.S. Department of Energy national lab, enabling collaborations, shared facilities access, and talent pipelines for regulated sectors. Research is supported by competitive federal funding from agencies such as NSF, NIH, USDA, DOE, and DoD. A dedicated technology transfer office manages IP, licensing, and startup support, complemented by incubator and pilot‑scale resources.